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Abstract
Background: Immune-mediated rejection of labeled cells is a general problem in transplantation
studies using cells labeled with any immunogenic marker, and also in gene therapy protocols. The
aim of this study was to establish a syngeneic model for long-term histological cell tracking in the
absence of immune-mediated rejection of labeled cells in immunocompetent animals. We used
inbred transgenic Fischer 344 rats expressing human placental alkaline phosphatase (hPLAP) under
the control of the ubiquitous R26 promoter for this study. hPLAP is an excellent marker enzyme,
providing superb histological detection quality in paraffin and plastic sections.
Results: Transplantation of cells from hPLAP transgenic (hPLAP-tg) F344 rats into wild-type (WT)
F344 recipients failed because of immune-mediated rejection. Here we show that this problem can
be overcome by inducing tolerance to the marker gene by transplantation of bone marrow from
hPLAP-tg F344 rats into WT F344 hosts after lethal irradiation, or by neonatal exposure of WT
F344 rats to hPLAP-tg F344 cells. As proof-of-principle, we injected bone marrow cells (BMC) from
hPLAP-tg rats into the knee joint of marker tolerant, bone marrow-transplanted WT rats, and
found successful engraftment and differentiation of donor cells. In addition, hPLAP-tg BMC injected
intravenously in neonatally tolerized WT F344 hosts could be traced in lymph nodes, 2 months
post-injection.
Conclusion: In combination with the excellent marker hPLAP, marker tolerant animals may open
up new perspectives for all experiments requiring long-term histological tracking of genetically
labeled cells.
Background
Cell therapy or cell-based gene therapy with adult
pluripotent mesenchymal stem cells is thought to revolu-
tionize the treatment of a large variety of diseases of vari-
ous organ systems in the future [reviewed in [1]]. To
further explore the therapeutic potential of regenerative
treatment protocols, appropriate animal models are nec-
essary that allow tracing the fate of individual donor or
manipulated cells in the host organism.
Tracing of cells requires labeling, and one standard
approach to label cells is to introduce marker genes into
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the genome of the cells under investigation. Marker genes
can either be permanently integrated into the genome of
transgenic animals so that all or at least some somatic cells
are permanently labeled, or wild-type cells can be trans-
duced with vectors containing the marker gene. A stable
genetic marker is especially useful for cell lineage experi-
ments, because the marker is expressed in whole progeny
of a specific cell.
Recent work from our laboratory has shown that human
placental alkaline phosphatase (hPLAP) is a highly suita-
ble marker enzyme for studies involving genetically
labeled cells in all tissues, including hard tissues, because
it survives not only paraffin but also modified methyl-
methacrylate (MMA) embedding [2,3]. hPLAP is a heat-
stable enzyme that is developmentally neutral in trans-
genic rats and mice [4]. In addition, endogenous alkaline
phosphatase activity can be totally blocked by heat inacti-
vation. Thus, this marker enzyme provides superb detec-
tion quality of labeled cells in the total absence of
background staining.
The present experiments employ R26-hPLAP transgenic
inbred Fischer 344 (hPLAP-tg) rats. The R26 promoter
represents a 0.8 kb fragment of the ROSA βgeo 26
(ROSA26) promoter sequence which has been found to
be especially useful to direct ubiquitous expression of
marker genes in mice and rats [4,5]. Transgenic mice and
rats expressing hPLAP under the control of the R26 pro-
moter show ubiquitous, uniform, and stable expression of
this genetic marker [4]. Therefore, hPLAP-tg F344 rats
were expected to be a highly useful model for labeling
donor cells in syngeneic transplantation studies [4].
However, during recent years, it has become increasingly
clear that membrane or even intracellular expression of
any foreign protein, and, thus, of any marker protein, will
elicit immune-mediated rejection of transplanted cells
carrying the marker gene in the recipients [6-10]. There-
fore, immune-mediated rejection of genetically altered
cells is a general and very significant problem in trans-
plantation studies using cells labeled with any marker
gene, and also in gene therapy protocols. This problem
has severely hampered the utility of animal models aimed
at testing the usefulness of cell and gene therapy, espe-
cially in long-term studies. Here we describe a novel in
vivo technology for studying labeled cells in the complete
absence of immune-mediated rejection in immunocom-
petent hosts.
Results
Immune response of wild-type rats after syngeneic 
transplantation of cells from hPLAP-tg rats
In order to test whether peripheral blood cells and bone
marrow cells from transgenic donors would survive and
proliferate in normal wild-type rats of the same inbred
strain, we intravenously injected peripheral blood leuko-
cytes (PBL) or bone marrow cells (BMC) from hPLAP-tg
donor rats daily for 1 week into wild-type F344 rats. How-
ever, histological analysis of lung, liver, spleen, lymph
nodes, and bone failed to show any evidence of hPLAP-
expressing cells from transgenic donors in the wild-type
recipients, suggesting that it was not possible to syngenei-
cally transplant cells from transgenic donors into wild-
type rats (Fig. 1). This finding prompted us to ask the
question whether expression of the transgene, and espe-
cially membrane expression of hPLAP, would induce the
formation of antibodies to hPLAP in the wild-type recipi-
ents. FACS (Fluorescence-Activated Cell Sorter) analysis
revealed that almost all PBL and BMC showed membrane
expression of the hPLAP enzyme in hPLAP-tg rats (Fig. 2A
and 2B). Immunization phenomena against hPLAP could
result in immune-mediated destruction of any hPLAP-
expressing cells in wild-type recipients, because the hPLAP
enzyme represents a foreign protein to the rat immune
system.
To test whether wild-type recipients develop antibodies
against hPLAP after injection of cells from transgenic
donor rats of the same strain, we intraperitoneally or sub-
cutaneously injected wild-type F344 rats with PBL from
hPLAP-tg rats three times with an 11-day interval between
the injections. Subsequently, serum from naïve wild-type
F344 rats or from wild-type F344 rats that had received
injections of PBL from hPLAP-tg rats was incubated with
PBL from transgenic rats, and the presence of antibody-
labeled cells was examined by FACS analysis. As expected,
serum from naïve wild-type rats that had never been in
contact with transgenic cells did not react with PBL from
transgenic rats (Fig. 2C). However, as shown in Fig. 2C,
repeated intraperitoneal injection of transgenic PBL
induced an antibody response in wild-type rats. Identical
results were obtained with subcutaneous injection (data
not shown). To test a cellular immune response to hPLAP
in wild-type rats, we performed mixed lymphocyte reac-
tion protocols. When spleen cells from naïve wild-type
rats were co-cultured with transgenic spleen cells, we did
not observe increased cell proliferation (Fig. 2D). How-
ever, cell proliferation was induced when spleen cells
from wild-type rats that had previously been exposed to
hPLAP-expressing cells were co-cultured with transgenic
cells. These data demonstrate that exposure to hPLAP-tg
cells induces immunization phenomena in wild-type rats,
explaining the abovementioned failure of the experiments
aimed at the syngeneic transplantation of transgenic cells
into normal wild-type recipients. To verify this hypothe-
sis, we transplanted skin from hPLAP-tg F344 rats into
naïve, 3-month-old wild-type F344 recipients (n = 3). All
recipients rejected the transgenic transplants within 2
weeks.BMC Biotechnology 2007, 7:30 http://www.biomedcentral.com/1472-6750/7/30
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FACS analysis of peripheral blood and bone marrow cells  from hPLAP-tg rats and immune response of wild-type rats  to transgenic cells Figure 2
FACS analysis of peripheral blood and bone marrow cells 
from hPLAP-tg rats and immune response of wild-type rats 
to transgenic cells. The single parameter fluorescence histo-
grams show hPLAP expression (mAb clone 8B6) on the 
majority of peripheral blood leukocytes (A) and practically all 
bone marrow cells (B) in hPLAP-tg rats (grey area), but no 
expression in wild-type rats (white area). When peripheral 
blood leukocytes from hPLAP-tg rats are incubated with 
serum from a naïve wild-type rat, and stained for bound anti-
bodies, no staining is seen (black curve, C). However, serum 
from the same wild-type intraperitoneally injected with cells 
from transgenic donors 3 times shows strong reactivity with 
peripheral blood leukocytes from hPLAP-tg rats (C, green, 
after 2 injections; red, after 3 injections), indicating the induc-
tion of circulating antibodies against transgenic cells in the 
recipient. Ten-thousand cells were analyzed in each sample. 
In a mixed lymphocyte reaction protocol (D), co-culture of 
hPLAP-tg spleen cells with spleen cells from wild-type rats 
previously injected with cells from hPLAP-tg rats, but not 
from naïve wild-type rats, caused increased cell proliferation. 
ConA was used as a positive control. 5 × 105 spleen cells per 
well were cultivated for 5 days (n = 8 wells each). * denotes 
P < 0.05 vs. indicated control group by one-way ANOVA fol-
lowed by least significant difference test.
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Transplantation of bone marrow cells (BMC) from hPLAP-tg  rats into wild-type F344 recipients Figure 1
Transplantation of bone marrow cells (BMC) from hPLAP-tg 
rats into wild-type F344 recipients. Transgenic, hPLAP-
labeled donor BMC were intravenously injected daily over 1 
week into wild-type rats. Lung (A), spleen (C), and lymph 
nodes (E) from transgenic animals show strong and ubiqui-
tous hPLAP staining. Similarly, osteocytes (arrowheads), 
osteoblasts (arrows), and all hematopoietic BMC show 
hPLAP staining in undecalcified MMA sections of ethanol-
fixed tibias from hPLAP-tg rats (G). However, staining is 
completely absent in lung (B), spleen (D), lymph nodes (F), 
bone (H), and bone marrow (H) of wild-type rats intrave-
nously injected with transgenic BMC over 1 week, 1 week 
after the last injection, indicating that syngeneic transplanta-
tion of transgenic BMC into wild-type recipients failed. The 
5-µm-thick paraffin and MMA sections shown in A-H were 
stained for hPLAP enzyme activity overnight at room tem-
perature after heat pretreatment, and were counterstained 
with nuclear fast red. Bar = 50 µm.
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Induction of tolerance by bone marrow transplantation
So far, our results indicated that hPLAP-tg rats could serve
as a very attractive model for regenerative therapies
because of ubiquitous and strong expression of the trans-
gene, and excellent preservation of the marker enzyme in
paraffin and MMA sections. However, immune-mediated
rejection of hPLAP-tg cells by wild-type rats exposed to
cells from transgenic donors made it impossible to use
this model for cell tracking. Therefore, we thought of a
way to overcome these problems. Previous studies have
shown that tolerance against intracellular xenogeneic
genes (for example GFP or neo, neomycin phosphotrans-
ferase) can be induced by busulfan treatment of wild-type
C57BL/6 mice, and subsequent transplantation of bone
marrow from GFP transgenic C57BL/6 mice [8], or by
transplantation of autologous hematopoietic stem cells
transduced with a neo marker gene in monkeys after total
body irradiation [9]. Based on these results, our idea was
to combine established methods of tolerance induction to
a specific marker with subsequent transplantation of oth-
erwise syngeneic cells labeled with the same marker in
order to avoid immune-mediated rejection of the labeled
cells.
To test the idea of employing marker tolerant animals as
a model for regenerative therapies, we initially used lethal
irradiation and transplantation of bone marrow from
hPLAP-tg F344 rats into wild-type F344 rats as proof-of-
principle to prevent the immune response after injection
of transgenic cells into wild-type rats. Because the rats are
of the same inbred strain, graft-versus-host reactions can
be ruled out a priori. Fig. 3A–C shows that in irradiated
wild-type rats transplanted with hPLAP-tg bone marrow
[WT (hPLAP-BMT)] all hematopoietic cells are of donor
origin, and stably express hPLAP, 4 weeks post-transplan-
tation. The superb histological detection quality of hPLAP
permits a clear distinction between wild-type cells of
recipient origin and hPLAP-expressing cells of donor ori-
gin (Fig. 3D–F). We found that a significant portion of
capillary endothelial cells, but not epithelial or mesenchy-
mal cells such as muscle cells, were of donor origin in
heart, kidney, and lung of irradiated WT (hPLAP-BMT)
rats (Fig. 3D–F and data not shown).
Utility of marker tolerant rats for cell tracking in 
regenerative medicine
An example of the usefulness of marker tolerant animals
for cell therapeutic studies is shown in Fig. 4A and 4B. In
this experiment, BMC from hPLAP-tg rats were injected
into the knee joint of irradiated WT (hPLAP-BMT) rats.
One week post-injection, the transgenic BMC had formed
a dense, 2 – 3 cells wide, layer on the intact articular carti-
lage surface. This finding suggests that these cells under-
went proliferation on the cartilage surface earlier. After 4
weeks, the genetically labeled cells displayed a more dif-
ferentiated fibroblast- or chondrocyte-like phenotype and
appeared to have become integrated into the surrounding
cartilage tissue of wild-type origin. This experiment under-
scores the potential usefulness and strengths of this tech-
nology, and clearly demonstrates that mesenchymal
precursors present in native bone marrow can adhere to
the articular cartilage surface and can, subsequently, dif-
ferentiate into a fibroblastic or chondrocytic phenotype.
Although potentially marred by immune-mediated rejec-
tion, similar findings have been reported in a goat model
of osteoarthritis, in which injection of autologous mesen-
Expression of hPLAP in tissues of irradiated wild-type rats  transplanted with bone marrow from hPLAP-tg rats [WT  (hPLAP-BMT)], 4 weeks post-transplantation Figure 3
Expression of hPLAP in tissues of irradiated wild-type rats 
transplanted with bone marrow from hPLAP-tg rats [WT 
(hPLAP-BMT)], 4 weeks post-transplantation. FACS analysis 
reveals hPLAP expression (mAb clone 8B6) on peripheral 
blood leukocytes (A) and bone marrow cells (B) in irradiated 
WT (hPLAP-BMT) rats (grey area) in contrast to wild-type 
rats (white area). All leukocytes in lymph nodes demonstrate 
clear hPLAP staining (C). In cross-sections of the ileum, ente-
rocytes and smooth muscle cells remain unstained, while 
cells in the submucosa and endothelial cells show intense 
hPLAP labeling (D). Cardiomyocytes (E) and renal tubular 
epithelial cells (F) are hPLAP negative cells of recipient origin, 
while a significant portion of capillary endothelium in heart 
and kidney is of donor origin as indicated by hPLAP labeling 
(arrows). Five-µm-thick paraffin sections of abdominal lymph 
node (C), ileum (D), heart (E), and kidney (F) stained for 
hPLAP activity and counterstained with nuclear fast red. Bar 
= 50 µm.
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chymal stem cells harvested from bone marrow, expanded
in culture, and transduced with GFP stimulated regenera-
tion of meniscal tissue and retarded progressive joint
destruction [11].
It is clear that the background of labeled hematopoietic
cells is an important shortcoming of irradiated WT
(hPLAP-BMT) rats, limiting this model to the study of
non-hematopoietic tissues. To test whether neonatal
exposure of wild-type F344 rats with cells from hPLAP-tg
F344 rats results in a sustainable tolerance to transgenic
tissue, we subcutaneously injected neonatal F344 wild-
type rats (n = 6) with whole blood from hPLAP-tg rats.
Four months later, skin of hPLAP-tg rats was transplanted
into these neonatally tolerized rats. The transgenic skin
grafts were accepted in 6 out of 6 rats, while a control lit-
termate not having received transgenic blood promptly
rejected the transgenic graft. Fig. 5A shows the margin of
the transgenic skin transplant in a marker tolerant rat, 4
weeks post-transplantation. It is evident that the border
between wild-type and transgenic tissue is sharply deline-
ated, and that capillaries from transgenic donor tissue
invade the surrounding wild-type skin (Fig. 5B).
These data clearly demonstrate that sustainable marker
tolerance also can be achieved by neonatal exposure of
wild-type F344 rats to hPLAP-expressing cells of the same
rat strain. Thus, any kind of hPLAP-labeled cell or tissue
from F344 rats can be transplanted and studied in these
marker tolerant F344 rats in the absence of immune-
Utility of neonatally tolerized rats for cell tracking Figure 5
Utility of neonatally tolerized rats for cell tracking. To test 
whether neonatal exposure of wild-type rats to transgenic 
cells results in long-lasting tolerance to the marker gene, skin 
from hPLAP-tg donor was grafted into a neonatally tolerized, 
4-month-old F344 wild-type rat. Four weeks post-transplan-
tation, the skin graft from the transgenic donor (upper part 
of the section) shows strong expression of hPLAP in all cells 
(A). The border between transgenic donor tissue and wild-
type recipient tissue is sharply delineated (arrowheads). A 
sebaceous gland (arrow in A), and a few capillaries (arrows in 
B) of transgenic donor origin are found in the surrounding 
wild-type skin. Keratinocytes do not cross the sharp border 
between wild-type and transgenic epidermis. Fig. 5B is a high 
power view of the frame shown in (A). When hPLAP-tg BMC 
were intravenously injected in neonatally tolerized F344 WT 
recipients, transgenic donor leukocytes are clearly present in 
an abdominal lymph node, 2 months post-injection (C-D). 
Fig. 5D is a high power view of the frame shown in (C). How-
ever, hPLAP-tg BMC injected intravenously in neonatally tol-
erized F344 WT recipients do not home to bone, bone 
marrow, or cartilage (E-F). Five-µm-thick paraffin or MMA 
sections of ethanol-fixed skin biopsy (A-B), abdominal lymph 
node (C-D), tibia (E), and knee joint (F) stained for hPLAP 
activity after heat pretreatment and counterstained with 
nuclear fast red. Bar = 100 µm (A, C) or 50 µm (B, D-F).
Recipient
AB
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Utility of irradiated, bone marrow-transplanted, marker tol- erant rats for regenerative studies and cell tracking Figure 4
Utility of irradiated, bone marrow-transplanted, marker tol-
erant rats for regenerative studies and cell tracking. When 
hPLAP-tg BMC were injected into the knee joint of irradiated 
WT (hPLAP-BMT) rats, there is a 2 – 3 cells wide layer of 
donor cells (arrowheads) on the cartilage surface, 1 week 
post-injection (A). Inset in (A) shows lack of hPLAP-staining 
in the articular cartilage of an irradiated WT (hPLAP-BMT) 
control rat not injected with transgenic BMC. Four weeks 
post-injection, transgenic donor cells have adopted a fibrob-
last-like (arrowheads) or chondrocyte-like (arrows) appear-
ance, and show incorporation into the surrounding 
chondrocyte matrix of host origin (B). Five-µm-thick unde-
calcified MMA sections of ethanol-fixed knee joints stained 
for hPLAP activity after heat pretreatment and counter-
stained with nuclear fast red. Bar = 50 µm.
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mediated rejection, and also in the absence of background
labeling. To examine the utility of this model for long-
term cell tracking, we intravenously injected neonatally
tolerized F344 rats with transgenic BMC (n = 4), and
assessed the occurrence of hPLAP-labeled cells 2 months
after cell administration in various organs. Two months
post-injection, we found hPLAP-labeled cells in lymph
nodes, but not in liver, heart, kidney, bone, or cartilage
(Fig. 5C–F and data not shown), with the exception of
extremely rare hPLAP-labeled endothelial cells in heart
and kidney (data not shown). hPLAP-stained cells were
totally absent in neonatally tolerized F344 controls which
had not received transgenic BMC as evidenced by histo-
logical and FACS analysis, ruling out the possibility of a
background of hPLAP-labeled cells in these rats (data not
shown).
Discussion
In this study we have shown 1) that hPLAP is an excellent
marker for histological tracking of genetically labeled
cells, 2) that a significant portion of endothelial cells is
bone marrow-derived in adult organs, and 3) that by
induction of selective tolerance to the marker protein it is
possible to track cells in immunocompetent, inbred rats
in the total absence of immune-mediated rejection of
labeled cells.
In line with previous reports our findings corroborate the
notion that hPLAP is a highly suitable marker enzyme for
histological tracking of genetically labeled cells in hard
and soft tissues [2,4], and we believe that the excellent
detection quality of hPLAP will set new standards in his-
tological cell tracking. Using this marker, we showed that
a significant portion of capillary endothelial cells were of
donor origin in heart, kidney, and lung of WT (hPLAP-
BMT) rats, 1 month post-transplantation. There is con-
flicting evidence whether endothelial cells are of hemat-
opoietic origin in postnatal organisms. Some studies with
genetically engineered mice revealed no evidence for a
hematopoietic origin of endothelial cells [12]. On the
other hand, in mice transplanted with bone marrow from
mice homozygous for the genomic globin/pBR322
marker, it has been reported that 0.2 – 1.4% of endothe-
lial cells are bone marrow-derived without tissue injury
during 4 months post-transplantation [13]. The much
higher portion of labeled endothelial cells found in our
study may be due to the higher sensitivity of hPLAP histo-
chemistry compared with the in situ hybridization tech-
nique necessary for visualization of the globin/pBR322
genomic marker, or due to species differences. Neverthe-
less, our data strongly suggest that bone marrow is a major
source of endothelial precursor cells, in line with the orig-
inal description of bone marrow-derived endothelial pre-
cursor cells and several other reports [14-16]. The reasons
why labeled endothelial cells were only very rarely
observed 2 months after intravenous BMC injection into
neonatally tolerized rats may be 1) the presumably low
number of endothelial precursors present in BMC prepa-
rations, and 2) a high turnover of endothelial cells in
many organs. Labeled endothelial cells could have been
replaced by unlabeled bone marrow-derived host cells
within the 2-month observation period. In line with the
latter hypothesis, labeled endothelial cells can be found at
higher frequency in solid organs of neonatally tolerized
rats injected with hPLAP-tg BMC, 1 week post-injection
(R.G. Erben, unpublished results).
hPLAP-tg rats express hPLAP mainly in the cell membrane
of most cell types as demonstrated by FACS analysis in our
study. We found that membrane expression of the genetic
marker induces strong humoral and cellular immune
responses in wild-type recipients that result in the rejec-
tion of intravenously infused cells from transgenic
donors. It is known from the work of other groups that
membrane expression of non-self proteins can elicit
immune-mediated rejection involving both B- and T-cell
responses in the recipients [6,7]. However, it has become
increasingly clear during recent years that immunization
phenomena against foreign proteins are not restricted to
membrane expression of these proteins. Intracellular
expression of foreign proteins also can induce strong T
cell-mediated immune responses [8-10]. Therefore,
immune-mediated rejection of genetically altered cells is a
general problem in transplantation studies using cells
labeled with any marker gene, and also in gene therapy
protocols. This shortcoming precludes unequivocal inter-
pretation of results from, especially long-term, transplan-
tation experiments with labeled cells.
Here we show that the problem of immune-mediated
rejection can be overcome by inducing tolerance to the
marker gene by transplantation of hPLAP-tg F344 bone
marrow into wild-type F344 recipients, or by exposure of
neonatal wild-type F344 rats to blood cells from hPLAP-tg
F344 rats. Our experiments have demonstrated that after
induction of marker tolerance, transgenic cells and tissues
could be successfully engrafted and traced in wild-type
rats. As an example of the utility of this concept, we dem-
onstrated hPLAP-labeled cells in lymph nodes, two
months after intravenous injection of hPLAP-tg BMC into
neonatally tolerized wild-type rats. Thus, we have estab-
lished a model in which immunocompetent, inbred ani-
mals are first made immunologically tolerant to the
marker gene that allows tracing of the transplanted cells.
In a second step, regenerative therapies with cells labeled
with the same marker gene can be tested in the complete
absence of immune-mediated rejection in immunocom-
petent hosts, avoiding the limitations of experiments with
immunodeficient SCID (severe combined immunodefi-
ciency) mice or immunosuppressed animals. In immune-BMC Biotechnology 2007, 7:30 http://www.biomedcentral.com/1472-6750/7/30
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privileged compartments such as the central nervous sys-
tem or in joints, immune-mediated rejection of labeled
cells may be delayed. For example, it was reported that
mesenchymal cells transduced with GFP survive for up to
12 weeks in the knee joint of goats [11]. Therefore, our
finding that hPLAP-tg BMC could be found 4 weeks post-
injection in the knee of irradiated WT (hPLAP-BMT) rats
does necessarily show that marker tolerant rats are supe-
rior to conventional models using wild-type animals for
regenerative studies in the knee. Nevertheless, immune-
mediated rejection of marker-expressing cells is a poten-
tial confounding factor also in immune-privileged com-
partments in long-term studies.
We used bone marrow transplantation and neonatal
induction of tolerance to the marker gene, but a plethora
of other strategies for tolerance induction is conceivable.
For example, inducible or tissue-specific promoters could
be used to reach this aim. Although our experiments were
performed using hPLAP as marker gene, the idea to use
marker tolerant animals for tracking of labeled cells is
applicable to all immunogenic marker proteins.
Conclusion
Our model is almost fully equivalent to the situation in
human patients using autologous adult stem cells for cell
and gene therapy, and we believe that hPLAP tolerant
inbred or cloned animals will not only be very useful for
the development of regenerative therapeutic protocols in
the future, but also for all experiments requiring long-
term histological tracking of labeled cells such as cell lin-
eage or stem cell experiments in various tissues. In addi-
tion, long-term tracking of transplanted cells is a sine qua
non to assess the long-term safety of regenerative thera-
pies. Therefore, another strength of this model is its ability
to address hitherto unresolved long-term safety issues of
cell and gene therapies in immunocompetent animals.
Methods
Animals
All experimental procedures were conducted in compli-
ance with prevailing animal welfare regulations. Hetero-
zygous male or female hPLAP-tg F344 rats were mated
with wild-type F344 rats, and the resulting wild-type and
heterozygous transgenic offspring were genotyped by
enzyme histochemistry using a drop of tail blood as
described [4]. The rats were housed in pairs at 24°C and a
12 h/12 h light/dark cycle with free access to tap water and
commercial rat diets (Altromin 1324 for maintenance and
1314 for breeding, Altromin, Lage, Germany).
Histology and hPLAP detection
Because hPLAP is sensitive to fixation with formalin [2],
tissues and bones were harvested and were fixed in 40%
ethanol at 4°C for 48 h. Subsequently, the tissue speci-
mens were dehydrated and embedded in paraffin or in a
modified MMA embedding mixture that preserves
enzyme activities and can also be used for immunohisto-
chemistry [3]. Five-µm-thick paraffin and MMA sections
were cut with a HM360 microtome (Microm, Walldorf,
Germany), and were mounted on slides pre-treated with
3-aminopropyltriethoxy-silane (APES, Sigma-Aldrich,
Deisenhofen, Germany).
Paraffin sections were deparaffinated using xylene,
whereas MMA sections were deplasticized using 2-meth-
oxyethylacetate as described [3]. Deparaffinated and
deplasticized sections were rehydrated and heated at
65°C for 30 min in deionized water to block endogenous
alkaline phosphatase activity. Sections were then incu-
bated in TRIS buffer (0.1 M Tris-HCl, pH 9.5, 0.1 M NaCl,
5 mM MgCl2) containing 0.17 mg/ml of the substrate 5-
bromo-4-chloro-3-indolyl phosphate (BCIP, Sigma) at
room temperature overnight. Subsequently, sections were
counterstained with nuclear fast red (Sigma), dehydrated,
and mounted using Vectamount (Vector, Burlingame, CA,
USA).
Flow cytometry
Peripheral whole blood was taken from a tail vein. BMC
were harvested from the tibia or femur by short centrifu-
gation of the bone, and were dispersed in PBS by repeated
pipetting. For labeling of cell surface hPLAP on peripheral
blood and BMC, cell suspensions (approximately 106 cells
each) were incubated with a monoclonal mouse anti-
hPLAP antibody (supernatant of clone 8B6, Dako) diluted
1:20 for 30 min on ice. Non-immune mouse IgG1
(MOPC-21, Sigma) and cell suspensions from wild-type
rats were used as negative controls. After washing twice,
the cells were incubated with rat-adsorbed, FITC-labeled
goat anti-mouse IgG antibody (Sigma) for 30 min on ice.
Prior to FACS analysis, erythrocytes were hemolyzed in
blood samples using FACS lysing solution (Becton Dick-
inson, Heidelberg, Germany). The analyses were per-
formed on a FACScan flow cytometer using CellQuest Pro
software (Becton Dickinson, Heidelberg, Germany).
To examine the presence of circulating anti-hPLAP anti-
bodies in serum of wild-type rats that had previously
received cells from hPLAP-tg rats, wild-type and trans-
genic peripheral blood cells were incubated for 30 min on
ice with 10 µl undiluted serum from naïve wild-type rats
or from wild-type rats that had received transgenic PBL
earlier. Using FITC-labeled goat anti-rat IgG antibody
(Serotec, Harwell, UK) as secondary antibody, the sam-
ples were processed and analyzed as described above.BMC Biotechnology 2007, 7:30 http://www.biomedcentral.com/1472-6750/7/30
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Transplantation of transgenic blood and bone marrow 
cells into wild-type recipients
In order to determine the fate of genetically labeled donor
cells in wild-type recipients, we intravenously injected 36
wild-type F344 rats with PBL or BMC (n = 18 each) iso-
lated from hPLAP-tg F344 rats. Transgenic rats were killed
by exsanguination from the abdominal aorta under keta-
mine/xylazine anesthesia. PBL were harvested using a
density gradient centrifugation kit (NycoPrep 1.077A,
Axis-Shield, Oslo, Norway), washed several times and
resuspended in PBS. The percentage of viable cells after
the isolation procedure was > 90% (trypan blue exclu-
sion). At the same time, BMC were harvested and washed
as described above. After isolation, all cells were resus-
pended in PBS, and were kept on ice until use. Isolated
genetically labeled PBL or BMC were injected intrave-
nously at a dose of 25 × 106 or 5 × 106 cells per animal,
respectively, into sex-matched wild-type recipients via a
lateral tail vein. All recipients received daily injections of
genetically labeled cells over 7 consecutive days (days 1 –
7). The recipient rats were killed on days 8, 15, 22, or 28
(n = 4 – 6 each for PBL and BMC recipients) by exsanguin-
ation from the abdominal aorta under ketamine/xylazine
anesthesia. From all recipient animals a variety of soft tis-
sues and bones were harvested, fixed in 40% ethanol at
4°C for 48 hours, and processed as described above.
Humoral and cellular immune response to transgenic cells
To examine the development of antibody production
against transgenic cells, we repeatedly exposed wild-type
rats to PBL from hPLAP-tg donors. The PBL were harvested
from hPLAP-tg rats as described above, and resuspended
in PBS. Subsequently, 1 × 106 PBL were subcutaneously or
intraperitoneally injected three times into wild-type F344
rats (1 rat each) with an 11-day interval between the injec-
tions. At baseline, and 10 days after each injection, blood
was drawn from a tail vein of the wild-type recipients to
obtain serum. For mixed lymphocyte reaction, spleen cells
were isolated by density gradient centrifugation (Nyco-
Prep 1.077A). The spleen cells from naïve wild-type rats or
from wild-type rats previously exposed to transgenic cells
(3 intraperitoneal injections at 10-day intervals) were co-
cultured with transgenic spleen cells for 5 days at a total
density of 5 × 105 cells per well (2.5 × 105 wild-type and
transgenic cells each). During the last 18 hours of culture,
3H thymidine (2 Ci/mmol) was added to quantify cell
proliferation. ConA (10 µg/ml) was used as a positive
control.
Lethal irradiation and bone marrow transplantation
To transplant bone marrow from hPLAP-tg rats into wild-
type F344 rats, wild-type animals (n = 6) were lethally
irradiated with a dosage of 8.5 Gy at 0.9473 Gy/min using
a cobalt-60 irradiator (Eldorado, Atomic Energy of Can-
ada, Ottawa, Canada). Four hours after the irradiation, the
rats were intravenously injected with 3 – 4 million BMC
isolated from hPLAP-tg rats as described above. To rule
out unsuccessful engraftments, the same injection of
freshly prepared transgenic BMC was repeated 24 hours
after the irradiation.
Intraarticular injection of genetically labeled cells
Next, we wanted to explore whether intraarticularly
injected BMC from hPLAP-tg rats would survive, prolifer-
ate, and differentiate in the knee joint of irradiated WT
(hPLAP-BMT) rats. For this experiment 6 male and female
wild-type F344 rats at the age of 3 months were lethally
irradiated and transplanted with BMC from hPLAP-tg
F344 rats. Two weeks after the bone marrow transplanta-
tion, 5 × 106  BMC isolated from hPLAP-tg rats were
injected once into the cavity of the left or right knee joint
under medetomidine/midazolam/fentanyl anesthesia.
The rats were killed 7 days or 28 days (n = 3 each) after the
intraarticular injection by exsanguination from the
abdominal aorta under ketamine/xylazine anesthesia. The
intact knee joints were harvested, trimmed, fixed in 40%
ethanol at 4°C for 48 hours, and embedded in MMA.
Frontal 5-µm-thick sections were cut as described above.
Induction of tolerance by neonatal exposure to transgenic 
cells
To induce tolerance to the marker gene by an alternative
method, 6 neonatal wild-type F344 rats pups, within 4
hours after birth, were subcutaneously injected once with
20 µl of whole blood from hPLAP-tg F344 donors. One
control litter mate did not receive transgenic cells. Four
months later, all 7 rats received skin grafts (approx. 1 cm2)
from sex-matched hPLAP-tg donors at the back under
anesthesia with medetomidine/midazolam/fentanyl. The
grafts were controlled daily. Four weeks post-transplanta-
tion, biopsies were taken under anesthesia from the mar-
gin of the skin grafts, fixed in 40% ethanol at 4°C for 48
hours, embedded in paraffin, sectioned at 5 µm thickness,
and stained for hPLAP enzyme activity as described above.
Tracking of transgenic cells in neonatally tolerized rats
Tolerance to hPLAP in F344 WT hosts was induced and
confirmed by skin grafts as described above. At the age of
4 months, 4 neonatally tolerized WT rats were intrave-
nously injected once with 108  BMC from hPLAP-tg
donors, and were killed 2 months post-injection. Various
tissues were harvested, fixed in 40% ethanol at 4°C for 48
hours, embedded in paraffin or MMA, sectioned at 5 µm
thickness, and stained for hPLAP enzyme activity as
described above. Neonatally tolerized control rats were
killed without prior injection of labeled cells to rule out a
background of labeled cells in the marker tolerant recipi-
ents.Publish with BioMed Central    and   every 
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Statistical analysis
Statistics were computed using SPSS for Windows 14.0
(SPSS, Chicago, IL). The data of the mixed lymphocytes
reaction experiments were analyzed using one-way analy-
sis of variance (ANOVA). When the analysis of variance
performed over all groups indicated a significant (p <
0.05) difference among the groups, statistical differences
between two groups were subsequently evaluated with
Fisher's least significant difference test. P values of less
than 0.05 were considered significant. The data in Figure
2D are given as means ± SEM.
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